Due to the fact that BioLingus drug administration is sublingual, and the use of a specific carrier molecule in the BioLingus formulation, the BioLingus technology is particularly effective for sublingual immuno therapy.
SLIT is already used more frequently for treating allergies. It is found to not only treat the symptoms, but the cause of the disease. Please see for instance following patient oriented video from the John Hopkins university.
Sublingual Immunotherapy (SLIT) for Allergy Treatment: Johns Hopkins | Q&A
Examples of this technology are sublingual interferon and sublingual interleukin-2.
In an experiment with very low dose IL-2 in peanut allergy, we have been able to demonstrate that our sublingual administration is as effective as injected IL-2, but at a dose which is 500 times lower. The reason is that our SLIT technology brings the molecules effectively in the lymphatic system, which is the heart of the immune system.
BioLingus has a project on to develop low dose IL-2 for treatment of early onset juvenile Type I diabetes. Low dose IL-2 in animal models has shown to balance Treg and Teff immune cells to reverse or prevent type I diabetes. Especially in children, having an oral therapy will make a difference.
In several animal and human studies it has been demonstrated that oromucosal interferon is as effective as parenteral interferon, but at much lower doses. As a result, side-effects of oral interferon are lower.
Oromucosal interferon is assumed to have a different immunomodulatory pathway, and stimulates production of endogenuous interferon gamma.